Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 11, 2023 08:30 ET
|
Elicio Therapeutics Inc.
ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCOAMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq...
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
August 09, 2023 08:00 ET
|
Elicio Therapeutics Inc.
AMP-CpG directed vaccine to lymph nodes inducing broad humoral and cellular immunity against multiple viral determinants expressed during the EBV life cycle AMP-CpG immunization generated persistent...
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
June 01, 2023 08:00 ET
|
Angion Biomedica Corp.
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
January 17, 2023 05:00 ET
|
Angion Biomedica Corp.
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will...
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
December 21, 2022 21:50 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 15, 2022 16:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
July 25, 2022 16:30 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
June 29, 2022 16:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022 16:05 ET
|
Angion Biomedica Corp.
-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a...
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
May 16, 2022 00:05 ET
|
Angion Biomedica Corp.
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF...